Epitalon
Also known as: Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly
What Is Epitalon?
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It was synthesized to mimic the active fraction of Epithalamin, a bovine pineal-gland extract from the same research group.
It is marketed on some of the most dramatic claims in the peptide world: telomerase activation, telomere elongation, “reversed biological aging,” normalized melatonin/circadian function, and reduced mortality. Those claims deserve careful scrutiny, because of where nearly all of the supporting research comes from.
What the Evidence Actually Shows — Read This Carefully
Two facts define the Epitalon evidence base, and both matter.
First: the single-lab origin problem. The overwhelming majority of Epitalon and Epithalamin research over roughly four decades comes from Khavinson’s group and closely affiliated Russian collaborators. Independent, non-Russian replication has been almost entirely absent. Western assessments — including the Alzheimer’s Drug Discovery Foundation’s Cognitive Vitality review — have specifically criticized the lack of independent replication and the sub-standard design of the human studies (small samples, inadequate blinding and randomization, much of it published only in Russian, none registered on ClinicalTrials.gov).
Second: there is now one independent replication — and it is in vitro only. In 2025, an independent UK group confirmed that Epitalon increases telomere length in human cell lines, via telomerase upregulation in normal cells and via the Alternative Lengthening of Telomeres (ALT) pathway in breast-cancer cell lines. This is the first credible Western confirmation of the mechanism — but it does nothing to validate any human longevity claim, and the ALT-in-cancer-cells finding is itself a potential safety flag worth noting.
The most impressive-sounding human data — a reported multi-fold reduction in mortality in elderly subjects (Khavinson & Morozov 2003) — used Epithalamin, the pineal extract, combined with Thymalin, not the isolated Epitalon tetrapeptide, and was not a blinded randomized controlled trial. It should not be cited as evidence that the Epitalon peptide extends human life.
Because the only independently replicated evidence is in vitro, the animal lifespan data come from the originating lab, and the human “longevity” claims are single-group, non-RCT, and unreplicated, we rate Epitalon animal-only — with the note that its telomere mechanism now has one independent in-vitro confirmation.
Legal and Regulatory Status
FDA: Removed from Category 2 on April 15, 2026. This is not authorization to compound — Epitalon is not yet on the 503A list, so licensed pharmacies still cannot lawfully compound it. PCAC reviews Epitalon on July 24, 2026; 503A listing (if it happens) would still require subsequent FDA rulemaking. Not FDA-approved for any indication.
WADA: Not explicitly named on the Prohibited List, but as a non-approved substance it would fall under S0 (non-approved substances), prohibited in sport at all times.
Common Vendor Claims vs. Reality
| What vendors say | What the evidence shows |
|---|---|
| ”Reverses aging / extends lifespan” | No human RCT; animal lifespan data from a single lab; human “mortality” data used the extract, not the peptide |
| ”Activates telomerase” | Supported in vitro (including one independent 2025 replication) — but a cell-line effect is not a proven clinical benefit |
| ”Clinically studied in humans” | Human studies are single-group, small, unblinded, and largely Russian-language; none meet Western RCT standards |
| ”Safe anti-aging peptide” | Long-term human safety data are absent; independent work found telomere lengthening via a pathway (ALT) associated with cancer cells |
The Bottom Line
Epitalon has one of the widest gaps between marketing and independently verified evidence of any peptide on the July 2026 PCAC agenda. The mechanism is real enough to have earned a single independent in-vitro confirmation; the human longevity claims are not supported by any study that meets modern standards. Removal from Category 2 changed its legal status, not the science — it remains unapproved and not lawfully compoundable.
Related: What Is the FDA Peptide Reclassification? | Early July 2026 Roundup